{ "meta": { "disclaimer": "Do not rely on openFDA to make decisions regarding medical care. While we make every effort to ensure that data is accurate, you should assume all results are unvalidated. We may limit or otherwise restrict your access to the API in line with our Terms of Service.", "terms": "https://open.fda.gov/terms/", "license": "https://open.fda.gov/license/", "last_updated": "2026-07-30", "results": { "skip": 0, "limit": 1, "total": 610 } }, "results": [ { "safetyreportversion": "2", "safetyreportid": "10029453", "primarysourcecountry": "IT", "occurcountry": "IT", "transmissiondateformat": "102", "transmissiondate": "20250409", "reporttype": "1", "serious": "1", "seriousnessdeath": "2", "seriousnesslifethreatening": "2", "seriousnesshospitalization": "2", "seriousnessdisabling": "2", "seriousnesscongenitalanomali": "2", "seriousnessother": "1", "receivedateformat": "102", "receivedate": "20140322", "receiptdateformat": "102", "receiptdate": "20250326", "fulfillexpeditecriteria": "1", "companynumb": "PHHY2014IT031524", "primarysource": { "reportercountry": "IT", "qualification": "3", "literaturereference": "Bianchi G V, Duca M, Sica L, Mariani G.. Metastatic breast cancer treated with lapatinib with a prolonged benefit: A case report and a review of therapeutic options available. TUMORI. 2013;99(6):269-72" }, "sender": { "sendertype": "6", "senderorganization": "NOVARTIS" }, "receiver": { "receivertype": "6", "receiverorganization": "FDA" }, "patient": { "patientonsetage": "53", "patientonsetageunit": "801", "patientsex": "2", "reaction": [ { "reactionmeddraversionpt": "27.1", "reactionmeddrapt": "Breast cancer metastatic", "reactionoutcome": "6" }, { "reactionmeddraversionpt": "27.1", "reactionmeddrapt": "Malignant neoplasm progression", "reactionoutcome": "6" }, { "reactionmeddraversionpt": "27.1", "reactionmeddrapt": "Metastases to liver", "reactionoutcome": "6" }, { "reactionmeddraversionpt": "27.1", "reactionmeddrapt": "Metastases to lymph nodes", "reactionoutcome": "6" }, { "reactionmeddraversionpt": "27.1", "reactionmeddrapt": "Palmar-plantar erythrodysaesthesia syndrome", "reactionoutcome": "6" }, { "reactionmeddraversionpt": "27.1", "reactionmeddrapt": "Asthenia", "reactionoutcome": "6" } ], "drug": [ { "drugcharacterization": "1", "medicinalproduct": "LETROZOLE", "drugauthorizationnumb": "20726", "drugadministrationroute": "065", "drugindication": "Breast cancer metastatic", "actiondrug": "5", "drugadditional": "3", "activesubstance": { "activesubstancename": "LETROZOLE" }, "openfda": { "application_number": [ "ANDA090934", "ANDA091191", "ANDA211717", "ANDA200161", "ANDA090289", "ANDA205869", "NDA020726" ], "brand_name": [ "LETROZOLE", "FEMARA" ], "generic_name": [ "LETROZOLE", "LETROZOLE TABLETS" ], "manufacturer_name": [ "Accord Healthcare, Inc.", "Dr. Reddy's Laboratories Limited", "Aurobindo Pharma Limited", "Natco Pharma Limited", "Teva Pharmaceuticals USA, Inc.", "Chartwell RX, LLC", "Breckenridge Pharmaceutical, Inc.", "Novartis Pharmaceuticals Corporation", "Avet Pharmaceuticals Inc.", "Yiling Pharmaceutical, Inc.", "Upsher-Smith Laboratories, LLC", "Carnegie Pharmaceuticals LLC" ], "product_ndc": [ "16729-034", "55111-646", "59651-180", "63850-0025", "0093-7620", "62135-491", "51991-759", "0078-0249", "23155-875", "69117-0004", "24979-726", "80005-139" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LETROZOLE" ], "rxcui": [ "200064", "153124" ], "spl_id": [ "4a681bf4-9779-a1b2-e063-6294a90a83db", "ec1b249b-2d77-55d9-0520-23884a961cf0", "2cd5dbfd-2432-4cea-bee2-6b710b5d28a2", "7917d6e0-df93-4c10-97c9-3d90b00b7bd4", "c91fb703-e253-490e-bb1d-48d054d81c6e", "456ed484-059b-2ee9-e063-6294a90a3f83", "432e6d32-0e6a-4020-8802-85e0def7c168", "28456311-e797-457f-8a9e-54dca5a7a336", "40009527-770b-8999-e063-6294a90a9946", "4721d1b1-3a04-27fb-e063-6394a90a7c1a", "4d5cb59c-11c3-4b0d-e063-6294a90a5b87", "9fb66539-2efe-47cc-9b78-85b096caac95" ], "spl_set_id": [ "c391fe11-fd47-4a35-af6d-c823ab7b8838", "6cfd29d7-f519-7b8c-4814-07b39f367f0d", "ff7325d2-3383-4ff9-a187-9350e3538640", "35c73219-c39e-4e10-b944-76009b061e79", "8ebda73d-82a3-4b17-8a81-a1f258003d32", "fa2d40a5-3504-44ef-8f5c-aa4c06308074", "63e54b62-a30d-4a56-9215-75e7a0b0bf02", "82b77d74-085f-45ac-a7dd-1f5c038bf406", "fe0e4d4b-436d-a36d-e053-6294a90a973d", "7b00e08c-9a1c-09e0-e053-2a91aa0a7638", "2d1f18f0-2c77-407c-b702-2d1b07f92510", "cb1da0ac-8db1-4482-824d-430511d1b7a0" ], "package_ndc": [ "16729-034-10", "16729-034-15", "16729-034-01", "16729-034-16", "16729-034-17", "16729-034-43", "55111-646-30", "55111-646-79", "55111-646-78", "59651-180-30", "59651-180-90", "63850-0025-1", "63850-0025-4", "0093-7620-56", "62135-491-30", "62135-491-90", "51991-759-33", "51991-759-10", "51991-759-90", "0078-0249-15", "23155-875-03", "23155-875-09", "23155-875-10", "69117-0004-1", "24979-726-07", "80005-139-08", "80005-139-10" ], "nui": [ "N0000175563", "N0000175080" ], "pharm_class_epc": [ "Aromatase Inhibitor [EPC]" ], "pharm_class_moa": [ "Aromatase Inhibitors [MoA]" ], "unii": [ "7LKK855W8I" ] } }, { "drugcharacterization": "1", "medicinalproduct": "LAPATINIB", "drugadministrationroute": "065", "drugindication": "Breast cancer metastatic", "drugstartdateformat": "610", "drugstartdate": "200906", "actiondrug": "5", "drugadditional": "3", "activesubstance": { "activesubstancename": "LAPATINIB" }, "openfda": { "application_number": [ "ANDA217968", "NDA022059", "ANDA203007" ], "brand_name": [ "LAPATINIB", "TYKERB" ], "generic_name": [ "LAPATINIB" ], "manufacturer_name": [ "Teva Pharmaceuticals, Inc.", "Novartis Pharmaceuticals Corporation", "Lupin Pharmaceuticals, Inc." ], "product_ndc": [ "0480-3237", "0078-0671", "68180-801" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "LAPATINIB DITOSYLATE" ], "rxcui": [ "672149", "672152" ], "spl_id": [ "f259a366-78fc-4919-9bcb-748314a0581c", "940eccaf-92b4-4562-8579-24a53c1bc48d", "d331d11d-21f4-472c-82d9-3b03b582026a" ], "spl_set_id": [ "b09abf73-1eef-4e12-b400-c030d546d223", "eee37f88-ec6a-4c30-b8aa-e2c71f93088c", "50d0dd0c-7682-43d0-aa1b-ca26e9181aee" ], "package_ndc": [ "0480-3237-51", "0078-0671-19", "68180-801-36" ], "unii": [ "G873GX646R" ] } }, { "drugcharacterization": "1", "medicinalproduct": "FULVESTRANT", "drugadministrationroute": "065", "drugindication": "Breast cancer metastatic", "actiondrug": "5", "drugadditional": "3", "activesubstance": { "activesubstancename": "FULVESTRANT" }, "openfda": { "application_number": [ "ANDA209714", "ANDA215234", "ANDA213553", "ANDA215077", "NDA210326", "ANDA209246", "ANDA210044", "ANDA214682", "ANDA205935", "ANDA211689", "ANDA207754", "ANDA211422", "ANDA215169", "NDA210063", "NDA021344" ], "brand_name": [ "FULVESTRANT", "CLIGAVYX", "FASLODEX" ], "generic_name": [ "FULVESTRANT" ], "manufacturer_name": [ "Meitheal Pharmaceuticals Inc", "Zydus Lifesciences Limited", "Northstar Rx, LLC,", "Alembic Pharmaceuticals Inc.", "Fresenius Kabi USA, LLC", "Dr.Reddy's Laboratories Inc", "Amneal Pharmaceuticals LLC", "Hikma Pharmaceuticals USA Inc.", "Sandoz Inc", "BluePoint Laboratories", "BluePoint Laboratories.", "Accord Healthcare Inc.", "GLENMARK PHARMACEUTICALS INC., USA", "Sagent Pharmaceuticals", "Athenex Pharmaceutical Division, LLC.", "Xiromed, LLC", "Avenacy, Inc.", "Eugia US LLC", "Avyxa Pharma, LLC", "Chia Tai Tianqing Pharmaceutical Group Co., Ltd.", "AstraZeneca Pharmaceuticals LP", "Zydus Pharmaceuticals USA Inc." ], "product_ndc": [ "71288-555", "70771-1626", "16714-070", "62332-650", "63323-715", "43598-262", "70121-1463", "0143-9022", "0781-3532", "68001-484", "68001-626", "16729-436", "0781-9055", "68462-317", "25021-471", "70860-211", "70700-284", "83634-203", "55150-394", "83831-159", "71731-6121", "68001-522", "0310-0720", "70710-1688" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAMUSCULAR", "INTRAVENOUS" ], "substance_name": [ "FULVESTRANT" ], "rxcui": [ "727762", "2745138", "727954" ], "spl_id": [ "2be67b09-31de-41b4-9468-a73a284abe41", "6908877d-222b-43e6-a7e9-f264fae84be4", "244e8f58-8aba-5ede-0b9d-a566f1021cfb", "8e24c62a-357f-4613-a936-d6e9088db32c", "c584c51e-3ce0-4682-a4dd-d0ac149201a8", "67af235f-7f8b-da5b-5eb6-91d0b20b2a9e", "84f58921-6fc9-4f8c-b074-a716239e52e2", "44dbf928-e93e-4f5e-8d1d-3b0e17f5d25f", "99e95543-2f0d-4992-80ff-00a4f92d6e06", "384e7b1e-9100-97cc-e063-6394a90afb72", "3ac255a1-c4ba-46f2-e063-6294a90a0628", "3001d1ed-b200-7d1b-e063-6394a90ab45f", "41e9778e-1f8d-4c65-baf4-f91f551fb2c7", "e98586b1-cab4-4f10-bf04-7e92f3ca2ff2", "7ee9004c-c1b0-4410-aaa7-7f6a52dca896", "c42819d9-59df-44fa-aa7a-e510311dbbb8", "fe82b170-2347-474e-93cb-c4fe66d1834e", "2cc985f3-36aa-f803-e063-6394a90a06f1", "6c925fcb-edcf-fdff-d723-603f4227821b", "6ecfd7da-f2b6-453d-8105-5f6e0bf5e95f", "01fb9018-5093-40e6-bfea-83dee3a5ffc0", "29f2a48e-b9af-486e-bc0c-eab3a1ce0b3c", "6cfbb5fe-940b-4ff1-89a7-e1dfc42b235b", "e4b34fb8-f651-8d00-e053-2995a90a3d2a", "9541dd80-09f9-4d3c-bb2a-fc354e198a2e", "b2f2e6fc-229a-46a6-ad64-02e665f8e942" ], "spl_set_id": [ "015fafb6-23f7-4566-9c23-386eee7b035d", "151b948a-3106-497a-b1c7-479307faeb89", "67566681-19b5-89df-2030-25df5b0cf641", "b02915fe-6c44-48c1-aaeb-997ddc59a595", "fabe9bd8-ac23-4df1-a89a-223d5cd38914", "2fc17ba3-83c7-a2b4-8a75-6a0cb1e07682", "f36f19ad-f044-4dba-80b6-d074ddffcd86", "306c283b-9abe-4985-856b-1957f1f3af8b", "141f439e-078c-4a59-acff-ebf7685f55b8", "bc7b4eac-3b63-53d2-e053-2995a90ad5e7", "57352662-d2fa-4dce-828f-4c51e46e0b4d", "b471eb51-488e-5312-e053-2a95a90a8116", "7a03f714-b109-4256-80a6-78c82127d624", "99cf8b69-4c23-4886-80e9-b23e348b5bd7", "a51aa693-b433-4b2d-a71b-9ba029b10ce3", "d5ae9e07-73b0-4063-a9e4-0ffc5614c2b8", "0f05b699-c440-42c1-9557-46759a10ab17", "8ed06e0e-c17b-4c71-8d03-888bcde4a638", "840cd7c0-9f33-f74e-f136-de7fe899bfb4", "f44cffcc-8f5e-4a4c-a36e-ab946ce86266", "80b6dfe6-449d-4e2f-af90-bfbf9b04163b", "e20d8ca3-8837-4003-8b01-1ebec342062a", "46086fe7-190d-4963-97bc-1fe22d36e6d2", "477098a1-cd37-48ad-b17f-aef610cb0f57", "83d7a440-e904-4e36-afb5-cb02b1c919f7", "994edf79-20a5-4e3a-bb35-c4fe3e65acba" ], "package_ndc": [ "71288-555-85", "71288-555-86", "70771-1626-2", "70771-1626-8", "16714-070-01", "16714-070-02", "62332-650-05", "62332-650-10", "63323-715-01", "63323-715-05", "43598-262-11", "43598-262-02", "43598-262-23", "70121-1463-3", "70121-1463-2", "0143-9022-01", "0143-9022-02", "0781-3532-01", "0781-3532-12", "68001-484-86", "68001-484-85", "68001-626-86", "68001-626-85", "16729-436-31", "16729-436-30", "0781-9055-01", "0781-9055-12", "68462-317-40", "68462-317-32", "70121-1463-1", "70121-1463-9", "25021-471-66", "25021-471-74", "70860-211-41", "70860-211-74", "70700-284-98", "83634-203-41", "83634-203-74", "55150-394-02", "83831-159-02", "71731-6121-1", "68001-522-86", "68001-522-85", "0310-0720-10", "70710-1688-2", "70710-1688-8" ], "nui": [ "N0000175582", "N0000000145", "N0000000168" ], "pharm_class_epc": [ "Estrogen Receptor Antagonist [EPC]" ], "pharm_class_moa": [ "Estrogen Receptor Antagonists [MoA]", "Selective Estrogen Receptor Modulators [MoA]" ], "unii": [ "22X328QOC4" ] } }, { "drugcharacterization": "1", "medicinalproduct": "CAPECITABINE", "drugadministrationroute": "065", "drugindication": "Breast cancer metastatic", "drugstartdateformat": "610", "drugstartdate": "200901", "actiondrug": "5", "drugadditional": "3", "activesubstance": { "activesubstancename": "CAPECITABINE" }, "openfda": { "application_number": [ "ANDA209365", "ANDA210203", "ANDA202593", "ANDA204345", "ANDA091649", "ANDA217237", "ANDA207456", "ANDA211724", "ANDA207652", "ANDA210604", "NDA020896", "ANDA204668" ], "brand_name": [ "CAPECITABINE", "CAPECITABINE 150MG", "XELODA", "CAPECITABINE 500MG" ], "generic_name": [ "CAPECITABINE" ], "manufacturer_name": [ "Cipla USA Inc.", "BluePoint Laboratories", "Dr. Reddy's Laboratories Limited", "NorthStar RxLLC", "Teva Pharmaceuticals USA, Inc.", "Teyro Labs Private Limited", "Armas Pharmaceuticals Inc.", "Accord Healthcare Inc.", "Lifestar Pharma LLC", "Novadoz Pharmaceuticals LLC", "Ascend Laboratories, LLC", "Aurobindo Pharma Limited", "H2-Pharma, LLC", "Camber Pharmaceuticals, Inc.", "CivicaScript LLC", "Quallent Pharmaceuticals Health LLC", "Sun Pharmaceutical Industries, Inc." ], "product_ndc": [ "69097-948", "69097-949", "68001-643", "68001-644", "68001-487", "68001-488", "55111-496", "55111-497", "72603-303", "0093-7473", "0093-7474", "82511-001", "82511-002", "72485-204", "16729-072", "16729-073", "70756-815", "70756-816", "72205-006", "72205-007", "67877-458", "67877-459", "59651-204", "59651-205", "61269-475", "61269-470", "31722-774", "31722-775", "82249-207", "82249-210", "82009-112", "62756-238", "62756-239", "72485-205" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "ORAL" ], "substance_name": [ "CAPECITABINE" ], "rxcui": [ "200327", "200328", "213292", "213293" ], "spl_id": [ "c1549b67-948e-402d-9ba4-6fc16237df8f", "498ba415-dab9-ce68-e063-6394a90af1b4", "fcfd1ff2-e3d6-dfff-e053-6394a90ababe", "25eb47d5-42ca-889b-6798-6f91d7795417", "571e3d84-50ae-dfbc-e063-6294a90a1d9b", "94cd2146-70ff-43e3-a896-b9e55d75540f", "2b3f98b5-d81c-d87d-e063-6294a90a7e87", "680dac89-d210-4eb8-a955-bf40e652c546", "0e1e6b8e-1e8f-3b26-e063-6294a90ad5fb", "42b31bbf-e149-216a-e063-6394a90ae1d5", "136d5048-1342-4a83-b6ce-db9f8933741c", "b664d5bf-34cd-480f-a055-e403628a4889", "eee71cc5-a7d5-4e51-ab02-2fae12418585", "32dd0155-c5cb-49c2-9b74-74f40df22df7", "519e85b4-ff10-917f-e063-6394a90a12df", "5a175994-25a9-4271-957f-9d8cc02fbfce", "752dff9e-8c95-001e-3602-7da1217d21bc", "8a24ef3b-b59a-4051-bf0d-a98eb6187ef2", "dad6f70f-70c9-4152-bd36-9cb3537239da" ], "spl_set_id": [ "2871c37d-5e55-437b-a434-fc86d845492a", "88c5af84-900a-4372-b056-bfea70c129cf", "bbb12406-ce02-3f31-e053-2995a90a0b16", "007e3432-c8aa-2a76-52ba-c346924c08a7", "0b59e98c-5b34-4b93-90f6-20526f4d4f88", "5753679a-506c-4ac4-b8b2-b27c664d1d40", "0c873e5b-51c2-4685-86c5-53f98563b093", "7f555b6b-60db-45e2-a61e-537e57f43fdc", "8345d55e-ad02-4726-a04b-1a46e3337a4b", "643a31d6-0e30-4602-a9b4-355fe944bfea", "29885ada-b743-419c-8f15-edd4247c76ca", "06a88b03-6c06-4dae-b3bc-1e8dd81c9067", "56441153-a1e5-4fdc-96d6-f21baa6b5fbe", "e702d84d-7162-4751-bf37-d724cc7e45a5", "3e7d6317-1439-4976-ae00-6f62619ec3dd", "4ec2cfc1-e8ca-4109-8b90-1aab07cbab21", "d23f023a-ea62-4ac0-f615-d5d26d59526d", "e3b1a2b5-f1ce-45ea-afd8-68aac53665fa", "f050d16c-ab76-489d-b92c-8c155b4e3f7c" ], "package_ndc": [ "69097-949-03", "69097-948-08", "68001-643-06", "68001-644-07", "68001-488-07", "68001-487-06", "55111-496-60", "55111-496-05", "55111-497-04", "55111-497-05", "72603-303-01", "0093-7473-06", "0093-7474-89", "82511-001-15", "82511-002-50", "72485-204-60", "16729-072-12", "16729-073-29", "70756-815-60", "70756-816-22", "72205-006-60", "72205-007-92", "67877-458-30", "67877-458-60", "67877-458-12", "67877-459-30", "67877-459-60", "67877-459-12", "59651-204-60", "59651-204-10", "59651-205-08", "59651-205-10", "61269-470-60", "61269-475-12", "31722-774-60", "31722-775-12", "31722-775-60", "82249-207-60", "82249-210-12", "82009-112-12", "62756-238-86", "62756-238-88", "62756-238-18", "62756-239-83", "62756-239-20", "62756-239-18", "72485-205-12" ], "nui": [ "N0000000233", "N0000175595" ], "pharm_class_moa": [ "Nucleic Acid Synthesis Inhibitors [MoA]" ], "pharm_class_epc": [ "Nucleoside Metabolic Inhibitor [EPC]" ], "unii": [ "6804DJ8Z9U" ] } }, { "drugcharacterization": "1", "medicinalproduct": "TRASTUZUMAB", "drugadministrationroute": "065", "drugindication": "Breast cancer metastatic", "actiondrug": "5", "drugadditional": "3", "activesubstance": { "activesubstancename": "TRASTUZUMAB" }, "openfda": { "application_number": [ "BLA761100", "BLA103792", "BLA761091" ], "brand_name": [ "ONTRUZANT", "HERCEPTIN", "HERZUMA" ], "generic_name": [ "TRASTUZUMAB" ], "manufacturer_name": [ "Organon LLC", "Genentech, Inc.", "Cephalon, Inc." ], "product_ndc": [ "78206-147", "78206-148", "50242-132", "63459-303", "63459-305" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "TRASTUZUMAB" ], "rxcui": [ "2289227", "2289232", "2289234", "2289237", "1922509", "1922512", "2107053", "2107058", "2169359", "2169362" ], "spl_id": [ "9b665849-a59e-4da6-ae51-36b3c885b85b", "7517f775-6a10-4ddd-8dfb-6704ece413d0", "49f6182a-5e0f-45ea-8a0f-b774ef28a98f" ], "spl_set_id": [ "ce2a2492-85e3-4b0a-872a-047f44e4203d", "492dbdb2-077e-4064-bff3-372d6af0a7a2", "ae71c003-883a-4cd8-ad50-e8cc9a54e971" ], "package_ndc": [ "78206-147-99", "78206-147-01", "78206-148-01", "78206-191-99", "78206-149-89", "50242-132-01", "63459-305-47", "63459-307-41", "63459-221-20", "63459-303-43" ], "nui": [ "N0000175661", "N0000020008" ], "pharm_class_epc": [ "HER2/neu Receptor Antagonist [EPC]" ], "pharm_class_moa": [ "HER2/Neu/cerbB2 Antagonists [MoA]" ], "unii": [ "P188ANX8CK" ] } }, { "drugcharacterization": "1", "medicinalproduct": "TRASTUZUMAB", "drugadministrationroute": "065", "actiondrug": "5", "drugadditional": "3", "activesubstance": { "activesubstancename": "TRASTUZUMAB" }, "openfda": { "application_number": [ "BLA761100", "BLA103792", "BLA761091" ], "brand_name": [ "ONTRUZANT", "HERCEPTIN", "HERZUMA" ], "generic_name": [ "TRASTUZUMAB" ], "manufacturer_name": [ "Organon LLC", "Genentech, Inc.", "Cephalon, Inc." ], "product_ndc": [ "78206-147", "78206-148", "50242-132", "63459-303", "63459-305" ], "product_type": [ "HUMAN PRESCRIPTION DRUG" ], "route": [ "INTRAVENOUS" ], "substance_name": [ "TRASTUZUMAB" ], "rxcui": [ "2289227", "2289232", "2289234", "2289237", "1922509", "1922512", "2107053", "2107058", "2169359", "2169362" ], "spl_id": [ "9b665849-a59e-4da6-ae51-36b3c885b85b", "7517f775-6a10-4ddd-8dfb-6704ece413d0", "49f6182a-5e0f-45ea-8a0f-b774ef28a98f" ], "spl_set_id": [ "ce2a2492-85e3-4b0a-872a-047f44e4203d", "492dbdb2-077e-4064-bff3-372d6af0a7a2", "ae71c003-883a-4cd8-ad50-e8cc9a54e971" ], "package_ndc": [ "78206-147-99", "78206-147-01", "78206-148-01", "78206-191-99", "78206-149-89", "50242-132-01", "63459-305-47", "63459-307-41", "63459-221-20", "63459-303-43" ], "nui": [ "N0000175661", "N0000020008" ], "pharm_class_epc": [ "HER2/neu Receptor Antagonist [EPC]" ], "pharm_class_moa": [ "HER2/Neu/cerbB2 Antagonists [MoA]" ], "unii": [ "P188ANX8CK" ] } }, { "drugcharacterization": "1", "medicinalproduct": "GONADORELIN", "drugadministrationroute": "065", "drugindication": "Breast cancer metastatic", "actiondrug": "5", "drugadditional": "3", "activesubstance": { "activesubstancename": "GONADORELIN" } }, { "drugcharacterization": "1", "medicinalproduct": "GONADORELIN", "drugadministrationroute": "065", "actiondrug": "5", "drugadditional": "3", "activesubstance": { "activesubstancename": "GONADORELIN" } } ] } } ] }